The present disclosure is directed to novel macrolide antibiotics of Formula 1 and pharmaceutically acceptable salts and prodrugs thereof; and the chemical syntheses and medical uses of these novel macrolide antibiotics for the treatment and/or management of infections caused by various aerobic and anaerobic gram-positive and gram-negative microorganisms as well as various mycobacteria.
本公开涉及一种新型大环内酯抗生素的公式1及其药用可接受的盐和前药;以及这些新型大环内酯抗生素的
化学合成和医学用途,用于治疗和/或管理由各种需氧和厌氧革兰氏阳性和阴性微
生物以及各种分枝杆菌引起的感染。